Role of targeted therapy in the treatment of HER-2-positive breast cancer brain metastases
Brain metastases are detectable in 25–35 % of patients with progressive HER-2-positve breast cancer. Even after spreading metastases into the brain, chemotherapy in combination with anti-HER- 2 therapy improves survival due to better control of the systemic disease. The paper presents the results of...
Saved in:
Main Authors: | G. A. Dashyan, V. F. Semiglazov, P. V. Krivorot’ko, T. Yu. Semiglazova, E. E. Topuzov, R. M. Paltuev, K. Yu. Zernov, V. S. Apollonova, S. S. Ereshchenko, A. V. Petrova, E. K. Zhil’tsova, O. A. Ivanova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2016-06-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/475 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
New prospects in the use of Kadcyla® in breast cancer
by: G. A. Dashyan, et al.
Published: (2015-11-01) -
Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01) -
Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer
by: Abbey Zidel, et al.
Published: (2025-05-01) -
Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01) -
Long-term survival after multidisciplinary treatments for HER2-positive advanced gastric cancer with multiple liver and lung metastases
by: Satoshi Yoshioka, et al.
Published: (2023-08-01)